CI 0694Alternative Names: Antigen Specific Immunomodulator; ASIM; Sulfasim
Latest Information Update: 02 Jul 2002
At a glance
- Originator Cortech
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Drug hypersensitivity
Most Recent Events
- 29 Feb 2000 Discontinued - Phase-I for Drug hypersensitivity in USA (unspecified route)
- 27 Jul 1999 No-Development-Reported for Drug hypersensitivity in USA (Unknown route)
- 27 May 1997 New profile